Quotient Therapeutics, a company pioneering somatic genomics to inform breakthrough medicines, announced that it has entered a multi-year research collaboration agreement with Merck, known as MSD outside of the United States and Canada, to discover novel drug targets in inflammatory bowel disease (IBD) using Quotient’s somatic genomics platform technology.
